Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneider, J. S.
Right arrow Articles by Tatarian, G. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneider, J. S.
Right arrow Articles by Tatarian, G. T.

Neurology, Vol 50, Issue 6 1630-1636, Copyright © 1998 by American Academy of Neurology

ARTICLES

Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study

JS Schneider, DP Roeltgen, EL Mancall, J Chapas-Crilly, DS Rothblat and GT Tatarian
Department of Pathology, Anatomy and Cell Biology,Thomas Jefferson University, Philadelphia, PA 19107, USA.

BACKGROUND/OBJECTIVE: Studies in animal models of Parkinson's disease (PD) suggest that GM1 ganglioside treatment can restore neurologic and dopaminergic function. In view of positive preclinical findings and the results of a previous open-label study demonstrating efficacy of GM1 in PD patients, this study compared effects of GM1 ganglioside and placebo on motor functions in PD patients. METHODS: Forty-five patients with mild to moderate PD were studied. The primary efficacy measure was change in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score. After three independent baseline assessments, patients received IV infusion of the test drug (1,000 mg GM1 or placebo) and then self- administered either GM1 or placebo twice daily (200 mg/day, subcutaneously) for 16 weeks. Patients were examined during monthly follow-up visits. RESULTS: There was a significant difference between groups in UPDRS motor scores at 16 weeks (p=0.0001). The activities of daily living portion of the UPDRS (off-period assessment) also showed a significant effect in favor of the GM1-treated patients (p=0.04). GM1- treated patients also had significantly greater mean improvements than placebo-treated patients in performance of timed motor tests including tests of arm, hand, and foot movements, and walking. GM1 was well tolerated and no serious adverse events were reported. CONCLUSIONS: This study demonstrates that GM1 ganglioside treatment enhances neurologic function significantly in PD patients. Further study is warranted to evaluate long-term effects of GM1 in PD patients and to elucidate further the mechanisms underlying patient improvements.


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
T. Ariga, M. P. McDonald, and R. K. Yu
Thematic Review Series: Sphingolipids. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review
J. Lipid Res., June 1, 2008; 49(6): 1157 - 1175.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B.M. Ravina, S.C. Fagan, R.G. Hart, C.A. Hovinga, D.D. Murphy, T.M. Dawson, and J.R. Marler
Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment
Neurology, April 22, 2003; 60(8): 1234 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
M. L. Allende, J. Li, D. S. Darling, C. A. Worth, and W. W. Young Jr.
Evidence supporting a late Golgi location for lactosylceramide to ganglioside GM3 conversion
Glycobiology, October 1, 2000; 10(10): 1025 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. Jankovic
New and Emerging Therapies for Parkinson Disease
Arch Neurol, July 1, 1999; 56(7): 785 - 790.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.